Farxiga
Farxiga contains dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2). It works by helping the kidneys eliminate glucose, water, and sodium from the body through urine, which helps lower blood sugar levels and reduces strain on the heart and kidneys.
Dosage by Body Weight
The standard starting dose is 5 mg taken orally once daily, usually in the morning, with or without food. Depending on tolerability and clinical need, the dose may be increased to 10 mg once daily.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients of this weight/age.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients of this weight/age.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients of this weight/age.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients of this weight/age.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients of this weight/age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Safety and effectiveness have not been established in pediatric patients of this weight/age. |
| 5-7 kg | Not indicated | N/A | Safety and effectiveness have not been established in pediatric patients of this weight/age. |
| 8-10 kg | Not indicated | N/A | Safety and effectiveness have not been established in pediatric patients of this weight/age. |
| 11-15 kg | Not indicated | N/A | Safety and effectiveness have not been established in pediatric patients of this weight/age. |
| 16-20 kg | Not indicated | N/A | Safety and effectiveness have not been established in pediatric patients of this weight/age. |
Formulation
Purpose
Used to improve glycemic control in adults with type 2 diabetes mellitus; to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and cardiovascular risk; to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease.
Generic Name
DapagliflozinScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.